Beam Therapeutics Inc. (NASDAQ:BEAM)
| Market Cap | $2.16B-11.5% |
| Revenue (ttm) | $146.64M+163.3% |
| Net Income | -$107.10M+74.2% |
| EPS | -$1.04+76.6% |
| Shares Out | 103.50M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | Nov 4, 2013 |
| Volume | 3,882,474 |
| Open | $20.54 |
| Previous Close | $20.94 |
| Day's Range | $20.54 - $22.10 |
| 52-Week Range | $20.44 - $38.26 |
| Beta | 2.22 |
| Analysts | Buy |
| Price Target | $79.00(+277.99%) |
| Earnings Date | Feb 23, 2027 |
About BEAM
Beam Therapeutics Inc., founded in 2017 and based in Cambridge, Massachusetts, operates as a pioneering biopharmaceutical firm. Its core mission involves engineering precise genetic remedies to tackle a spectrum of severe human ailments, primarily within the United States. The company's developmental portfolio features several key candidates: BEAM-101 is being advanced to treat both sickle cell disease and beta thalassemia. BEAM-102 is specifically designed for addressing sickle cell disease. BEAM-201, an allogeneic chimeric antigen receptor T-cell therapy, is under investigation for individuals suffering from relapsed or refractory T-cell acute lymphoblastic leukemia. BEAM-301 is a liver-targeted candidate aimed at patients afflicted with Glycogen Storage Disease Type Ia. Beyond these flagship programs, Beam Therapeutics is also engaged in devising treatments for alpha-1 antitrypsin deficiency, various ocular conditions, and other disorders impacting the liver, muscular system, and central nervous system. To further its research and development objectives, Beam Therapeutics has forged numerous strategic alliances and partnerships. These include collaborations with Boston Children's Hospital; a research and clinical trial agreement with Magenta Therapeutics, Inc.; a licensing deal with Sana Biotechnology, Inc.; and a research partnership with the Institute of Molecular and Clinical Ophthalmology Basel. Additionally, the company maintains research collaborations with both Pfizer Inc. and Apellis Pharmaceuticals, Inc., alongside a comprehensive collaboration and license agreement with Verve Therapeutics, Inc.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
Analyst consensus
4 firms rating BEAM in the last 3 months, one vote each. Issuer-paid research is not counted.
Next catalysts
- Feb 23, 2027Earnings report
$BEAM stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in BEAM holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by BEAM's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
BEAM Estimated quarterly lobbying spending
Source: U.S. Senate LDA
BEAM Revenue by Segment
| Stock-based compensation | $18.55M | 98.37% |
| License and collaboration revenue | $307.00K | 1.63% |
As of: Q3 2026 (Sep 30, 2026) · Source: SEC EDGAR (10-Q)
U.S. Patents
New BEAM patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to BEAM from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in BEAM
| ARKKARK Innovation ETF | $240.79M |
| XBIState Street SPDR S&P Biotech ETF | $73.86M |
| VTIVanguard Morningstar Total Stock Market ETF | $70.53M |
| VBVanguard Morningstar Small-Cap ETF | $63.05M |
| ARKGARK Genomic Revolution ETF | $60.21M |
| IWMiShares Russell 2000 ETF | $54.41M |
Estimated from each fund’s disclosed top holdings × AUM
Bull Case vs Bear Case
AI-generated from BEAM’s recent data — informational, not investment advice
What’s Behind the Score
News check: Risto-cel met primary sickle cell trial endpoints; analyst upgrade with higher price target offsets modest stock dip from initial reaction.
Recent Insider Activity
Insider Score Trend Over Time
+0.0 since Sep 27Composite Insider Score (0–100) recomputed on each scoring run from live SEC Form 4 data.
Frequently Asked Questions
ETFs that hold this stock
| TYNE | Direxion Nanotechnology ETF | 11.13% |
| ARKG | ARK Genomic Revolution ETF | 4.00% |
| NIFE | Direxion Fallen Knives ETF | 3.21% |
| ARKK | ARK Innovation ETF | 2.60% |
| HLTH | Tema Healthcare AI ETF | 2.21% |
| GNOM | Global X - Genomics & Biotechnology ETF | 1.85% |
| WDNA | WisdomTree BioRevolution Fund | 1.47% |
| TDNA | T. Rowe Price Biotech ETF | 1.13% |
| MEDX | Horizon Kinetics Medical ETF | 1.03% |
| XBI | State Street SPDR S&P Biotech ETF | 0.84% |
| GNMX | Corgi ETF Trust I - Corgi Genomics & Precision Medicine ETF | 0.84% |
| BBC | Virtus Biotech Clinical Trials ETF | 0.66% |
Weight is the stock’s share of each fund’s holdings.
